产品编号
1724060
CAS 号
54573-75-0
中文名称
(1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5R,E)-5,6-二甲基庚-3-烯-2-基)-7a-甲基六氢-1H-茚-4(2H)-亚乙基)-4-亚甲基环己烷-1,3-二醇
MDL 号
MFCD00871065
分子量
412.65
存储条件
网页展示纯度为入库指导纯度值,各批次间存在一定差异,实际纯度以收货为准
熔点
沸点
闪点
旋光
描述
TPSA
40.46
LogP
6.6118
H_Acceptors
2
H_Donors
2
Rotatable_Bonds
5
[1]. Francesca Tentori, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015 Jan 7;10(1):98-109.
[2]. Frank Gotch, et al. Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration. Blood Purif. 2010;29(2):163-76.
[3]. Jason Gee, et al. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jun;73(9):970-8.
[4]. Jun H Choi, et al. Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats. J Card Fail. 2011 Dec;17(12):1051-8.
[5]. Neil Kumar, et al. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations. Am J Nephrol. 2009;29(2):71-8.
警示图
警示词
Danger
危险申明
H300
警告申明
P264-P270-P330-P405-P501
GHS 编码
GHS06
危险类别
6.1
UN 编码
2811
包装等级
Ⅲ
现货供应
专业护航
售后无忧
品质保障
无需凑单